Clinical Trial Search

Primary: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24 — -0.67 units on a scale — p=<0.0001

Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) for…

Primary: Change in Self-reported Overall Function From Baseline to 12 Weeks — 0.4; -0.6; -1.37; -0.32 units on a scale — p=0.2691

Primary: Opiate Consumption — 64.8; 81.3 Opiate Consumption (IV MME)

Primary: Pharmacokinetic (PK): Area Under the Curve Zero to Infinity (AUC[0-∞]) for LY3314814 — 3200 Nanogram * hour per milliliter (ng*h/mL)

Primary: Percentage of Participants With a Maximum NRS Score of 1 or Less During the 28 Days Before the Final Dose of Study Drug — 57.6; 3.1 percentage of participants — p=<0.0001

Primary: Speech Production: Effect Size for Treated Items — 6.84; 6.14 effect size — p=.254

Primary: Number of Participants With Adverse Drug Reactions — 47; 5; 6; 1 Participants

Primary: Percentage of Participants With Total PBAC Score of <10 From Week 6 to 12 — 82.2; 83.1 percentage of participants — p=0.0013

Primary: Opiate Consumption — 48.6; 53.9 IV MME

Primary: Absolute Bioavailability of LY3314814 — 60.5; 59.2 nanogram*hour per milliliter per mg

Primary: Time to Progression — 7.8 Months

Primary: Percentage of Patients With Obesity — 58.2; 51.7; 57.4; 54.2 Percentage of patients

Primary: Number of Participants Who Experienced Death or Rehospitalization Due to Cardiovascular or Renal Cause — 1; 2 Participants

Primary: Indicators / Minute — 1.925; 0.23; 0.4; 0.45 indicators/minute — p=0.992